{"id":99583,"date":"2025-03-28T16:33:58","date_gmt":"2025-03-28T16:33:58","guid":{"rendered":"https:\/\/www.mymsd.ch\/fr\/?p=99583"},"modified":"2025-12-02T11:13:13","modified_gmt":"2025-12-02T11:13:13","slug":"melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie","status":"publish","type":"post","link":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/","title":{"rendered":"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" height=\"487\" width=\"1024\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Banner-Melanome-SGDV.jpg?w=1024\" alt=\"Personnes dans des sc\u00e8nes de la vie quotidienne, banni\u00e8re KEYTRUDA pour les stades de m\u00e9lanome IIB\u2013IV\" class=\"wp-image-99588\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Banner-Melanome-SGDV.jpg 1156w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Banner-Melanome-SGDV.jpg?resize=300,143 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Banner-Melanome-SGDV.jpg?resize=768,365 768w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Banner-Melanome-SGDV.jpg?resize=1024,487 1024w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Banner-Melanome-SGDV.jpg?resize=320,152 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Banner-Melanome-SGDV.jpg?resize=120,57 120w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--8bcf303c9a79fc753e31e1fd9a7ec4d7 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--0117b270846919f40f85dc983e4a6504 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color has-teal-500-color has-text-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--55322bf5ca666358e9732843b5d46db8\">De nombreux patient(e)s atteint(e)s d&rsquo;un m\u00e9lanome au stade IIB et IIC ne peuvent pas \u00eatre gu\u00e9ris uniquement par r\u00e9section.<sup>2<\/sup><strong> <\/strong><\/h4>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--834e09d0e8008b5563a3cade47ad86a4\">Les r\u00e9cidives surviennent fr\u00e9quemment dans le m\u00e9lanome des stades IIB et IIC<sup>3<\/sup><br><sup><br><\/sup><\/h5>\n\n\n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--8065bc59aa11f399c07e2daa6fa752e1\">\n                    <img loading=\"lazy\" decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--full wp-image-99627\"\n        src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Melanome-SGDV-Recidives_2.jpg?quality=80&#038;lossy=1\"\n        width=\"1024\"\n        height=\"500\"\n                alt=\"Chart showing recurrence and metastasis rates in melanoma stages IIB and IIC, including affected organs\"\n            \/>\n            <\/figure>\n\n\n\n<div style=\"height:80px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section class=\"mhh-mcn-v1-section mhh-mcn-v1-section--622e3b94525fa8e034e73a9e535a0af0 mhh-mcn-section mhh-mcn-v1-section--align-full\">\n    <div class=\"mhh-mcn-container\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--17f6538b06deca3a48faab22a3651292\"><mark class=\"has-inline-color has-teal-700-color\">Pour les patient(e)s atteint(e)s d\u2019un m\u00e9lanome de stade IIB\/IIC, une option th\u00e9rapeutique de MSD est disponible.<sup>1,*<\/sup><\/mark><\/h4>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--01568c642d91a4b504722e28e1982e7f\"><mark class=\"has-inline-color has-black-color\">Th\u00e9rapie adjuvante avec KEYTRUDA\u00ae pour vos patient(e)s atteint(e)s de m\u00e9lanome<sup>1<\/sup><\/mark><\/h5>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--43190feba650d33eda7862f7782e7bdc\"><mark class=\"has-inline-color has-black-color\">KEYTRUDA\u00ae est approuv\u00e9 en monoth\u00e9rapie pour le traitement adjuvant des adultes atteints d\u2019un m\u00e9lanome de stade IIB ou IIC compl\u00e8tement r\u00e9s\u00e9qu\u00e9.<sup>1,*<\/sup> L\u2019\u00e9tude KEYNOTE-716 a montr\u00e9 qu\u2019un traitement pr\u00e9coce avec KEYTRUDA\u00ae permettait de r\u00e9duire le risque de r\u00e9cidive et d\u2019am\u00e9liorer la survie sans r\u00e9cidive.<sup>4<\/sup><\/mark><\/p>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a669c37d825d4288df7260bad1c4bd49\"><mark class=\"has-inline-color has-black-color\">Dans l\u2019\u00e9tude d&rsquo;homologation &nbsp;KEYNOTE-716, le traitement par KEYTRUDA\u00ae a<br>entra\u00een\u00e9 une r\u00e9duction de 38 % du risque de r\u00e9cidive chez les patient(e)s atteint(e)s d\u2019un m\u00e9lanome de stade IIB\/IIC par rapport au placebo (donn\u00e9es \u00e0 4 ans, suivi m\u00e9dian de 52,8 mois).<sup>4<\/sup> Le profil de s\u00e9curit\u00e9 correspondait au profil de s\u00e9curit\u00e9 connu, sans nouveaux signaux de risque identifi\u00e9s.<sup>4<\/sup><\/mark><\/p>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--2001b418a922d011b6d9536b2f7449eb\"><mark class=\"has-inline-color has-black-color\">Avantage clinique significatif par rapport au placebo<sup>4<\/sup><\/mark><\/h5>\n\n\n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--43c6c31d25cf7031bf1db75fa88c7c21\">\n                    <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--full wp-image-99590\"\n        src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Melanome-SGDV-RFS-DMFS.jpg?quality=80&#038;lossy=1\"\n        width=\"1024\"\n        height=\"390\"\n        loading=\"lazy\"        alt=\"Graph showing 38% risk reduction of recurrence and 41% risk reduction of distant metastases in melanoma\"\n            \/>\n            <\/figure>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--274cd97cb1b3f6a2d2451041227d4477\"><strong><mark class=\"has-inline-color has-teal-700-color\">Orientez vos patient(e)s atteint(e)s d\u2019un m\u00e9lanome de stade IIB\/IIC vers un(e) oncologue!<\/mark><\/strong><\/h5>\n\n    <\/div>\n<\/section>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--77f3f8c8dc4c6ae1d576bcac24401d63\">KEYTRUDA\u00ae \u2013 une option de traitement pour les patient(e)s atteint(e)s de m\u00e9lanome depuis 2015<sup>5<\/sup><\/h4>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c254b288d2f55c82f7103f68d063573f\">Chez MSD, nous nous engageons continuellement \u00e0 proposer des th\u00e9rapies offrant aux patient(e)s atteint(e)s de cancer une meilleure qualit\u00e9 de vie et plus de temps. KEYTRUDA\u00ae est approuv\u00e9 pour le traitement du m\u00e9lanome aux stades \u00e0 haut risque IIB\/IIC*, III ainsi qu\u2019au stade IV chez l\u2019adulte.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section class=\"mhh-mcn-v1-section mhh-mcn-v1-section--02f986916a6b4ea0177e1614e6ecac04 mhh-mcn-section mhh-mcn-v1-section--align-full\">\n    <div class=\"mhh-mcn-container\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--b9fcc12a577863593e6ea7e9114d08fb\"><mark class=\"has-inline-color has-white-color\"><strong>Prof. Dr. med. Reinhard Dummer sur les progr\u00e8s de l&rsquo;immunoth\u00e9rapie<\/strong><\/mark><\/h4>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b5b78f1f0eb24fc9538ab1458d9ebc40\">Voir la vid\u00e9o<\/p>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--0d6a6701423a3dcdbf27bea764b7b037 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--e47724cee3c7c96d8c6656c53e4250cb mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<div  class=\"inpsyde-brightcove__player\" style=\"position: relative\">\n\n    \n    <video-js class=\"video-js vjs-16-9\" data-embed=\"default\" data-player=\"wpDhMYhEmz\" data-account=\"4090876667001\" data-video-id=\"6364902980112\" aria-label=\"Video\" controls poster-url=\"https:\/\/cf-images.us-east-1.prod.boltdns.net\/v1\/static\/4090876667001\/2f976770-1371-42a2-995c-8b26ae92f641\/c58db5c1-582d-497c-afb1-aebe7373a0fd\/1280x720\/match\/image.jpg\"><\/video-js>\n\n        <img\n        class=\"inpsyde-brightcove__poster\"\n        src=\"https:\/\/cf-images.us-east-1.prod.boltdns.net\/v1\/static\/4090876667001\/2f976770-1371-42a2-995c-8b26ae92f641\/c58db5c1-582d-497c-afb1-aebe7373a0fd\/1280x720\/match\/image.jpg\"\n        alt=\"\"\n        fetchpriority=\"high\"\n        decoding=\"async\"\n        aria-hidden=\"true\"\n    \/>\n    \n    \n    <script src=\"https:\/\/players.brightcove.net\/4090876667001\/wpDhMYhEmz_default\/index.min.js\"><\/script>\n<\/div>\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--4dc02dab9203018ab5c8669a6afbcaf7 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8cd002304e8f594a71b5024c5c4e5593\"><mark class=\"has-inline-color has-white-color\"><em>\u00abLorsque j&rsquo;ai la premi\u00e8re conversation avec un patient atteint d&rsquo;un m\u00e9lanome m\u00e9tastatique, je lui dis: <\/em><br><br><em>Notre objectif est de vous gu\u00e9rir.\u00bb<\/em><\/mark><\/p>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n    <\/div>\n<\/section>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--857729e0f3d9405b5be10cb3d27e5049 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--e612495a05097bc4c92d758968d95817 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--ddf9280803222ae4354f5f63e6451086 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--7c034143385fdcec0019eba2a83964a5 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-8 mhh-mcn-column--l-8\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--b1da719b878e33ec65888ff1a1180e26\">Plus d\u2019informations<br>sur les options th\u00e9rapeutiques avec KEYTRUDA\u00ae<br>pour le m\u00e9lanome<\/h4>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--db55b62fef4de05ff2c202ee3e071d20\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--b9ac643bd2eba9c8807603d05398bd40 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/melanom\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Keytruda Indications Melanom\">\n                    <span class=\"mhh-mcn-v1-link__label\">Vers les options th\u00e9rapeutiques<\/span>\n                <\/a><\/div>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--b59e0b97adc405bcc1fee78e50faa3e6 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-4 mhh-mcn-column--l-4\">\n    \n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--85331bca58a83272320d7ba92091dff7\">\n                    <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--medium wp-image-92728\"\n        src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/08\/Melanom.png?w=300&#038;quality=80&#038;lossy=1\"\n        width=\"300\"\n        height=\"300\"\n        loading=\"lazy\"        alt=\"Illustration of skin cross-section with hair follicles\"\n            \/>\n            <\/figure>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\r\n<div class=\"inpsyde-iframe is-responsive has-transparent-background-color\">\r\n    <iframe loading=\"lazy\" height=\"400\" referrerpolicy=\"no-referrer-when-downgrade\" title=\"Ce contenu vous a-t-il \u00e9t\u00e9 pertinent ?\" src=\"https:\/\/go.screver.com\/msd-ch-cx\/newsroom-articles?lang=fr&amp;hideHeader=true\" width=\"100%\"><\/iframe>\r\n<\/div>\n\n\n<section class=\"mhh-mcn-v1-section mhh-mcn-v1-section--d2f3fde8e10593f5d1d238fcfb769d5f mhh-mcn-section mhh-mcn-v1-section--align-full\">\n    <div class=\"mhh-mcn-container\">\n    \n\n<h3 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color has-text-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--e94657ebad452fee692fbe855d3bd372\" style=\"color:#000000\">Related Content<\/h3>\n\n\n<div class=\"mhh-mcn-v1-content-items mhh-mcn-v1-content-items--fded659466e9d8429769ff09542f4809 wp-block-mconnect-theme-curated-content mhh-mcn-layout--columns mhh-mcn-columns mhh-mcn-v1-columns--7c9930767fa566be6604ec19528b2970 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-columns-inner\">\n        <div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--4ea4865308cc37353c845cf438278c32 mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--032ce9b8b35741f7f37535980b2d4558 with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-94136\"\n        src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2024\/02\/MSD2931-KEYTRUDA-Melanom-KN716-Bilder-fuer-mymsd-600x400-FR-V02-150.png?w=1250&#038;quality=80&#038;lossy=1\"\n        width=\"1250\"\n        height=\"833\"\n        loading=\"lazy\"        alt=\"\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"This item has been tagged as: M\u00e9lanome\">\n    M\u00e9lanome<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/nouvelle-option-de-traitement-du-melanome-avec-keytruda\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        Nouvelle option de traitement du m\u00e9lanome avec KEYTRUDA\u00ae \u00a0    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Swissmedic a approuv\u00e9  KEYTRUDA\u00ae pour le traitement du m\u00e9lanome \u00e0 haut risque de stade IIB\/IIC.<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    En savoir plus<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n<div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--4d95e816351f2e06a602a546192dfdd8 mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--6040abb8349950df2d3c0ef20d0c53d3 with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-93544\"\n        src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/MSD2916-Header-FR-635x475px-V01.jpg?w=635&#038;quality=80&#038;lossy=1\"\n        width=\"635\"\n        height=\"475\"\n        loading=\"lazy\"        alt=\"\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"This item has been tagged as: M\u00e9lanome\">\n    M\u00e9lanome<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/les-deux-options-de-dosage-de-keytruda-dans-le-melanome-sont-desormais-remboursees-par-les-caisses-maladie\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        Les deux options de dosage de KEYTRUDA\u00ae dans le m\u00e9lanome sont d\u00e9sormais rembours\u00e9es par les caisses-maladie    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Nouveau : les deux options de dosage de KEYTRUDA\u00ae (Pembrolizumab) dans le m\u00e9lanome sur la Liste des sp\u00e9cialit\u00e9s (LS) de l&rsquo;Office f\u00e9d\u00e9ral de la sant\u00e9 publique (OFSP)<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    En savoir plus<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n<div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--1e834485fb9fa78561d514570e048e4f mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--b5ce075545e07667ee7f45c5adea9226 with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-85250\"\n        src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/06\/NOUVEAU-Partie-consacree-article-2-FR-featured.png?w=1380&#038;quality=80&#038;lossy=1\"\n        width=\"1380\"\n        height=\"1380\"\n        loading=\"lazy\"        alt=\"\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"This item has been tagged as: M\u00e9lanome\">\n    M\u00e9lanome<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanoma-on-msd-gesundheit-ch\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        NOUVEAU: Partie consacr\u00e9e au m\u00e9lanome sur notre portail d\u00e9di\u00e9 aux patient.e.s \u00abmsd-gesundheit.ch\u00bb    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Transmettre de fa\u00e7on simple des informations attest\u00e9es sur le plan m\u00e9dical? C\u2019est pr\u00e9cis\u00e9ment l\u2019objectif de notre portail d\u00e9di\u00e9 aux patient.e.s \u00abmsd-gesundheit.ch\u00bb.<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    En savoir plus<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n    <\/div>\n\n    <\/div>\n\n    <\/div>\n<\/section>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--1df10307e1925828dedd9c606ec15f4d\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--875692e5cbece2659e5d362f80170231\" href=\"mailto:%20dpoc.switzerland@msd.com\" target=\"_self\" aria-label=\"Des exemplaires des publications de l&#039;\u00e9tude peuvent \u00eatre demand\u00e9s \u00e0 dpoc.switzerland@msd.com si n\u00e9cessaire.\">\n                    <span class=\"mhh-mcn-v1-link__label\">Des exemplaires des publications de l&rsquo;\u00e9tude peuvent \u00eatre demand\u00e9s \u00e0 dpoc.switzerland@msd.com si n\u00e9cessaire.<\/span>\n                <\/a><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--0674b49db5eb91b5f21db9b359514a27\"><strong><em>Abr\u00e9viations<\/em><\/strong><em>:<\/em><\/h5>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--22ae4a041d0264c7641f1b64a1ae6836\"><em><strong>CI<\/strong>: Intervalle de confiance; <\/em><strong><em>DMFS: <\/em><\/strong><em>survie \u00e0 distance sans m\u00e9tastases  (distant metastasis-free survival); <strong>HR:<\/strong> Hazard Ratio; <strong>Q3W:<\/strong> toutes les trois semaines; <strong>Q6W:<\/strong> toutes les six semaines ; <strong>RFS:<\/strong> rezidivfreies \u00dcberleben (recurrence-free survival).<\/em><\/p>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--84de053801a71045aa178c393f524399\"><strong><em>R\u00e9f\u00e9rences:<\/em><\/strong><\/h5>\n\n\n\n<ol class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--1eaaf9eea05e5691c3d6dffc9d4fe38c mhh-mcn-list mhh-mcn-v2-clist--ordered mhh-mcn-v2-clist--ordered-decimal\" dir=\"ltr\" lang=\"en-US\" start=\"1\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Information professionnelle de KEYTRUDA\u00ae (Pembrolizumab), <a href=\"https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&amp;lang=DE&amp;authNr=66231&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.swissmedicinfo.ch<\/a>, derni\u00e8re consultation 21.3.2025.<br>* En raison de donn\u00e9es cliniques incompl\u00e8tes au moment de l&rsquo;examen de la demande, ces indications sont autoris\u00e9es pour une dur\u00e9e limit\u00e9e (art. 9a LPTh). L&rsquo;autorisation \u00e0 dur\u00e9e limit\u00e9e est imp\u00e9rativement li\u00e9e \u00e0 la satisfaction de charges en temps opportun. Une fois ces charges satisfaites, l&rsquo;autorisation \u00e0 dur\u00e9e limit\u00e9e pourra \u00eatre transform\u00e9e en autorisation ordinaire.<sup>1<\/sup><\/em><br>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Gershenwald JE, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer (AJCC) Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(6):472 \u2013 492.<\/em><br>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939-946. doi: 10.1245\/s10434-016-5642-0. <\/em><br><em><strong>Conception de l&rsquo;\u00e9tude<\/strong>: \u00e9tude r\u00e9trospective d\u2019une base de donn\u00e9es prospective de 738 patient(e)s adultes atteint(e)s de m\u00e9lanome cutan\u00e9 primaire r\u00e9s\u00e9qu\u00e9 au stade pathologique II (AJCC, 7e \u00e9dition). Tou(te)s les patient(e)s ont \u00e9t\u00e9 trait\u00e9(e)s au Memorial Sloan Kettering Cancer Center entre janvier 1993 et d\u00e9cembre 2013. Les patient(e)s ont subi un staging pathologique des ganglions lymphatiques par biopsie du ganglion sentinelle ou dissection \u00e9lective des ganglions lymphatiques. La dur\u00e9e m\u00e9diane de suivi des patient(e)s atteint(e)s de m\u00e9lanome de stade IIB et IIC \u00e9tait respectivement de 50.2 mois et de 46.2 mois.<br><\/em>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Luke JJ, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200\/JCO.23.02355. Online ahead of print.\u00a0<\/em><br><em><strong>Conception de l&rsquo;\u00e9tude<\/strong>: \u00e9tude de phase III multicentrique, en double aveugle, randomis\u00e9e, contr\u00f4l\u00e9e par placebo (partie 1 en aveugle, partie 2 Rechallenge\/Crossover ouvert): 976 patient(e)s (\u2265 12 ans) atteint(e)s de m\u00e9lanome de stade IIB ou IIC compl\u00e8tement r\u00e9s\u00e9qu\u00e9 (population ITT), randomisation (1:1): KEYTRUDA\u00ae 200 mg ou 2 mg\/kg pc jusqu\u2019\u00e0 un maximum de 200 mg (patients p\u00e9diatriques \u2265 12 ans) toutes les 3 semaines (n = 487)* versus placebo (n = 489). Traitement des patients initialement jusqu\u2019\u00e0 1 an ou jusqu\u2019\u00e0 la survenue d\u2019une r\u00e9cidive ou d\u2019une toxicit\u00e9 inacceptable (partie 1), en cas de r\u00e9cidive traitement Rechallenge (partie 2) jusqu\u2019\u00e0 2 ans jusqu\u2019\u00e0 la survenue d\u2019une r\u00e9cidive ou d\u2019une toxicit\u00e9 inacceptable. Les patients qui, en dehors de la chirurgie, avaient re\u00e7u auparavant un autre traitement du m\u00e9lanome, \u00e9taient exclus de l\u2019\u00e9tude. Crit\u00e8res primaires d\u2019efficacit\u00e9: survie sans r\u00e9cidive (RFS) dans l\u2019ensemble de la population. La RFS \u00e9tait \u00e9valu\u00e9e par l\u2019investigateur et d\u00e9finie comme la p\u00e9riode entre le moment de la randomisation et le moment de la survenue de la premi\u00e8re r\u00e9cidive (locale, r\u00e9gionale ou m\u00e9tastases \u00e0 distance) ou du d\u00e9c\u00e8s, selon l\u2019\u00e9v\u00e9nement survenant en premier. *Pour des informations d\u00e9taill\u00e9es sur la posologie, voir l\u2019information professionnelle.<\/em><br>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em><a href=\"https:\/\/compendium.ch\/product\/1346803-keytruda-inf-konz-100-mg-4ml\">https:\/\/compendium.ch\/product\/1346803-keytruda-inf-konz-100-mg-4ml<\/a>, derni\u00e8re consultation 21.3.2025.<\/em>    <\/li>\n\n<\/ol>\n\n\n\n<p dir=\"ltr\" lang=\"fr-FR\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ca68b839df191381222fb74d227cb537\"><em>Avant la prescription, veuillez consulter l\u2019information professionnelle compl\u00e8te publi\u00e9e sur&nbsp;<a href=\"https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&amp;lang=FR&amp;authNr=66231&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo.ch<\/a>.<\/em><\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--b9a503ca35726566f723197db49c82d6\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--9754509d1060f83c9fd60934aaa4583f mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.swissmedicinfo-pro.ch\/showText.aspx?textType=FI&#038;lang=FR&#038;authNr=66231&#038;supportMultipleResults=1\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Information professionnelle de KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Information professionnelle de KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--ebbd98e1920f22be30745091efbee86b\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--3d0961a6d64998076e84ff69689969e3 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>De nombreux patient(e)s atteint(e)s d&rsquo;un m\u00e9lanome au stade IIB et IIC ne peuvent pas \u00eatre gu\u00e9ris uniquement par r\u00e9section.<\/p>\n","protected":false},"author":1413,"featured_media":99632,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","hide_featured_image":true,"primary_tag":2248,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[792,791],"tags":[598,914,2248],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[957],"ga4_page_businessunit":[963],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1206],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[627,931],"tx-product":[642],"tx-pathology":[825],"tx-content-type":[795],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-99583","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-onco-news","category-oncology","tag-keytruda","tag-melanoma","tag-melanome-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie - MyMSD.ch FR Onco News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie - MyMSD.ch FR Onco News\" \/>\n<meta property=\"og:description\" content=\"De nombreux patient(e)s atteint(e)s d&#039;un m\u00e9lanome au stade IIB et IIC ne peuvent pas \u00eatre gu\u00e9ris uniquement par r\u00e9section.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch FR\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T16:33:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T11:13:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"sthost\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"sthost\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/\"},\"author\":{\"name\":\"sthost\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43\"},\"headline\":\"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie\",\"datePublished\":\"2025-03-28T16:33:58+00:00\",\"dateModified\":\"2025-12-02T11:13:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/\"},\"wordCount\":433,\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg\",\"keywords\":[\"Keytruda\",\"melanoma\",\"Melanome\"],\"articleSection\":[\"Onco News\",\"Oncology\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/\",\"name\":\"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie - MyMSD.ch FR Onco News\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg\",\"datePublished\":\"2025-03-28T16:33:58+00:00\",\"dateModified\":\"2025-12-02T11:13:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"name\":\"MyMSD.ch FR\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43\",\"name\":\"sthost\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g\",\"caption\":\"sthost\"},\"url\":\"https:\/\/www.mymsd.ch\/fr\/author\/sthost\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie - MyMSD.ch FR Onco News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/","og_locale":"fr_FR","og_type":"article","og_title":"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie - MyMSD.ch FR Onco News","og_description":"De nombreux patient(e)s atteint(e)s d'un m\u00e9lanome au stade IIB et IIC ne peuvent pas \u00eatre gu\u00e9ris uniquement par r\u00e9section.","og_url":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/","og_site_name":"MyMSD.ch FR","article_published_time":"2025-03-28T16:33:58+00:00","article_modified_time":"2025-12-02T11:13:13+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg","type":"image\/jpeg"}],"author":"sthost","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"sthost","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#article","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/"},"author":{"name":"sthost","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43"},"headline":"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie","datePublished":"2025-03-28T16:33:58+00:00","dateModified":"2025-12-02T11:13:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/"},"wordCount":433,"publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg","keywords":["Keytruda","melanoma","Melanome"],"articleSection":["Onco News","Oncology"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/","url":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/","name":"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie - MyMSD.ch FR Onco News","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg","datePublished":"2025-03-28T16:33:58+00:00","dateModified":"2025-12-02T11:13:13+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#primaryimage","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/03\/F-Teaser-Melanome-SGDV_2.jpg","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/melanome-le-risque-de-recidive-peut-etre-reduit-par-immunotherapie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"M\u00e9lanome : le risque de r\u00e9cidive peut \u00eatre r\u00e9duit par immunoth\u00e9rapie"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/fr\/#website","url":"https:\/\/www.mymsd.ch\/fr\/","name":"MyMSD.ch FR","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/fr\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43","name":"sthost","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g","caption":"sthost"},"url":"https:\/\/www.mymsd.ch\/fr\/author\/sthost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts\/99583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/users\/1413"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/comments?post=99583"}],"version-history":[{"count":31,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts\/99583\/revisions"}],"predecessor-version":[{"id":102889,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts\/99583\/revisions\/102889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media\/99632"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media?parent=99583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/categories?post=99583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tags?post=99583"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_audience?post=99583"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_birn_id?post=99583"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_branding?post=99583"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_businessunit?post=99583"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_campaign?post=99583"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=99583"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=99583"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=99583"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_experience?post=99583"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_indication?post=99583"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_material_intent?post=99583"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_product?post=99583"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_region?post=99583"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=99583"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-therapeutic-area?post=99583"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-product?post=99583"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-pathology?post=99583"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-content-type?post=99583"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-active-ingredient?post=99583"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/access?post=99583"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_status?post=99583"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_role?post=99583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}